Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance
Current Oncology · 18.06.2025 · 32 (6) · 359
DOI: 10.3390/curroncol32060359 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 18.06.2025. Verfasst von Braden Millan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural Research Program of the National Cancer Institute, National Institutes of Health, NIH Medical Research Scholar Program.
Abstract (Originalsprache)
Molecular testing in renal cell carcinoma (RCC) has allowed for a better understanding of the biology of both sporadic and hereditary diseases, where genetic testing is currently recommended in the guidelines for a select population with risk factors. Historically, screening, surveillance, and management decisions were based solely on clinicopathologic data; however, we now know that molecular profiling can enhance decision making, altering the treatment plan, approach, or selection of systemic therapy and enhancing the delivery of precision oncologic care. Advances and the increasing availability of next-generation sequencing technologies have improved the identification of germline and somatic variants in key RCC-associated genes. Given the molecular heterogeneity of RCC, these modern methods can identify unique genetic events that occur in a single individual, allowing for distinction between a metachronous tumor from metastases. Separate four-tier systems have been proposed to categorize germline and somatic variants according to their clinical significance, which should be highlighted. Additionally, emerging technologies, such as liquid biopsy, show potential for enhancing precision oncology in RCC. With this said, challenges, such as variant interpretation, ethical considerations, and accessibility, persist. This review examines the molecularly defined RCC, genetic testing methodologies currently available, their current clinical applications, limitations, and future directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Ruben Blachman-Braun, Mark W Ball
Förderung
- Intramural Research Program of the National Cancer Institute
- National Institutes of Health
- NIH Medical Research Scholar Program
Zitieren
APA
Millan, B., Loebach, L., Blachman-Braun, R., Patel, M. H., Saini, J., Linehan, W. M., & Ball, M. W. (2025). Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. Current Oncology, 32(6), 359. https://doi.org/10.3390/curroncol32060359
Vancouver
Millan B, Loebach L, Blachman-Braun R, Patel MH, Saini J, Linehan WM, et al. Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance. Current Oncology. 2025;32(6):359. doi:10.3390/curroncol32060359
BibTeX
@article{Millan2025,
author = {Millan, Braden and Loebach, Lauren and Blachman-Braun, Ruben and Patel, Milan H and Saini, Jaskirat and Linehan, W Marston and Ball, Mark W},
title = {Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {6},
pages = {359},
doi = {10.3390/curroncol32060359}
}
EUVIMED